T1	Participants 146 194	patients with chronic idiopathic urticaria (CIU)
T2	Participants 422 465	AH-resistant and AH responder CIU patients.
T3	Participants 466 535	CIU patients with treatment failure under fexofenadine at 180 mg q.d.
T4	Participants 589 680	Those with significant improvement of urticaria activity score under fexofenadine at 180 mg
T5	Participants 849 932	The control group consisted of sex- and age-matched patents with allergic rhinitis.
T6	Participants 1093 1205	Forty-six subjects were included in the CIU group, 21 were in the R-CIU group, and 44 were in the control group.
